Redeye update its projections and valuation after Beyond Frames Q3 result. Our sales and earnings projections for 2025-2026 remain largely unchanged. The stock’s weak momentum has persisted since our latest research update, likely driven by two consecutive quarters of negative year-over-year growth. Despite this, Beyond Frames appears attractively valued for a company in a high-growth phase.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/